Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors

Br J Haematol. 2022 Feb;196(3):e21-e26. doi: 10.1111/bjh.17864. Epub 2021 Oct 10.

Wei Yee Chan^{1

2}, Lara Howells¹, William Wilson³, Emilie Sanchez⁴, Louise Ainley^{1

2}, Selina J Chavda^{1

2}, Emma Dowling⁵, Nuno Correia⁵, Catherine S Y Lecat^{1

2}, Annabel McMillan^{1

2}, Brendan Wisniowski¹, Shameem Mahmood¹, Xenofon Papanikolaou¹, Lydia Lee^{1

2}, Jonathan Sive¹, Charalampia Kyriakou¹, Ashutosh Wechalekar¹, Rakesh Popat¹, Neil Rabin¹, Eleni Nastouli⁴, Kwee L Yong^{1

2}, Ke Xu¹

¹ Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
² Research Department of Haematology, UCL Cancer Institute, London, UK.
³ Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK.
⁴ Department of Clinical Virology, University College London Hospitals NHS Foundation Trust, London, UK.
⁵ HCA Healthcare at University College London Hospitals NHS Foundation Trust, London, UK.

No abstract available

Keywords: humoral response; multiple myeloma; plasma cell disorders; severe acute respiratory syndrome coronavirus-2; vaccination response.

Publication types